<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01488708</url>
  </required_header>
  <id_info>
    <org_study_id>13811</org_study_id>
    <secondary_id>H9B-MC-BCDX</secondary_id>
    <nct_id>NCT01488708</nct_id>
  </id_info>
  <brief_title>On Open-Label Study in Participants With Systemic Lupus Erythematosus</brief_title>
  <acronym>Illuminate-X</acronym>
  <official_title>A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this SLE study is to evaluate the long-term safety and efficacy of LY2127399
      in eligible SLE participants who have completed the core studies (NCT01196091) (NCT01205438).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>Baseline through 4 years</time_frame>
    <description>A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With a Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With a Reduction in Steroid Dose</measure>
    <time_frame>Baseline through 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SLE Disease Activity Index</measure>
    <time_frame>Baseline, 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of New Severe SLE Flares</measure>
    <time_frame>Baseline through 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Improvement in Lupus Quality of Life</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anti-double-stranded Deoxyribonucleic Acid Level</measure>
    <time_frame>Baseline, 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1518</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Connective Tissue Disease</condition>
  <condition>Autoimmune Disease</condition>
  <arm_group>
    <arm_group_label>LY 2127399 Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2127399 Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2127399</intervention_name>
    <description>120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.</description>
    <arm_group_label>LY 2127399 Q2W</arm_group_label>
    <arm_group_label>LY2127399 Q4W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
    <arm_group_label>LY 2127399 Q2W</arm_group_label>
    <arm_group_label>LY2127399 Q4W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have completed 52 weeks of treatment in core studies (NCT01196091) (NCT01205438)

          -  Given written informed consent

          -  Test negative for pregnancy at the time of enrollment

          -  Agree to use a reliable method of birth control

        Exclusion Criteria:

          -  Unwilling to comply with study procedures

          -  Any condition that renders the participants unable to understand the nature and scope
             and possible consequences of the study

          -  Any condition that in the opinion of the investigator poses an unacceptable risk to
             the participants if study drug would be administered
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY(1-877-285-4559 or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern Time (UTC/GMT-5 hours, EST</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2011</study_first_submitted>
  <study_first_submitted_qc>December 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2011</study_first_posted>
  <results_first_submitted>March 24, 2018</results_first_submitted>
  <results_first_submitted_qc>May 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2018</results_first_posted>
  <disposition_first_submitted>March 10, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 10, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 24, 2016</disposition_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus</keyword>
  <keyword>SLE</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Immune System Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LY 2127399 Q2W</title>
          <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
        </group>
        <group group_id="P2">
          <title>LY2127399 Q4W</title>
          <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="940"/>
                <participants group_id="P2" count="578"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="937"/>
                <participants group_id="P2" count="578"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participated in Follow Up</title>
              <participants_list>
                <participants group_id="P1" count="810"/>
                <participants group_id="P2" count="526"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="940"/>
                <participants group_id="P2" count="578"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LY 2127399 Q2W</title>
          <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
        </group>
        <group group_id="B2">
          <title>LY2127399 Q4W</title>
          <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="940"/>
            <count group_id="B2" value="578"/>
            <count group_id="B3" value="1518"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.6" spread="12.12"/>
                    <measurement group_id="B2" value="40.4" spread="11.35"/>
                    <measurement group_id="B3" value="42.4" spread="11.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="880"/>
                    <measurement group_id="B2" value="527"/>
                    <measurement group_id="B3" value="1407"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="454"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="612"/>
                    <measurement group_id="B2" value="314"/>
                    <measurement group_id="B3" value="926"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="579"/>
                    <measurement group_id="B2" value="337"/>
                    <measurement group_id="B3" value="916"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="449"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecuador</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guatemala</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belarus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macedonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tunisia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA-SLEDAI) Score</title>
          <description>SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" spread="3.81"/>
                    <measurement group_id="B2" value="4.9" spread="3.74"/>
                    <measurement group_id="B3" value="5.2" spread="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-dsDNA Antibody Level (IU)</title>
          <units>International Unit/Milliliter (IU/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.9" spread="102.03"/>
                    <measurement group_id="B2" value="92.3" spread="102.35"/>
                    <measurement group_id="B3" value="86.4" spread="102.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Events (AEs)</title>
        <description>A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.</description>
        <time_frame>Baseline through 4 years</time_frame>
        <population>All participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY 2127399 Q2W</title>
            <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Q4W</title>
            <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs)</title>
          <description>A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.</description>
          <population>All participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="578"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="65.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With a Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response</title>
        <time_frame>Week 48</time_frame>
        <population>Zero participants analyzed. Data was not collected for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LY 2127399 Q2W</title>
            <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Q4W</title>
            <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With a Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response</title>
          <population>Zero participants analyzed. Data was not collected for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With a Reduction in Steroid Dose</title>
        <time_frame>Baseline through 4 years</time_frame>
        <population>Zero participants analyzed. Data was not collected for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LY 2127399 Q2W</title>
            <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Q4W</title>
            <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With a Reduction in Steroid Dose</title>
          <population>Zero participants analyzed. Data was not collected for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SLE Disease Activity Index</title>
        <time_frame>Baseline, 4 years</time_frame>
        <population>Zero participants analyzed. Data was not collected for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LY 2127399 Q2W</title>
            <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Q4W</title>
            <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SLE Disease Activity Index</title>
          <population>Zero participants analyzed. Data was not collected for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of New Severe SLE Flares</title>
        <time_frame>Baseline through 4 years</time_frame>
        <population>Zero participants analyzed. Data was not collected for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LY 2127399 Q2W</title>
            <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Q4W</title>
            <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of New Severe SLE Flares</title>
          <population>Zero participants analyzed. Data was not collected for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Improvement in Lupus Quality of Life</title>
        <time_frame>4 years</time_frame>
        <population>Zero participants analyzed. Data was not collected for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LY 2127399 Q2W</title>
            <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Q4W</title>
            <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Improvement in Lupus Quality of Life</title>
          <population>Zero participants analyzed. Data was not collected for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Anti-double-stranded Deoxyribonucleic Acid Level</title>
        <time_frame>Baseline, 4 years</time_frame>
        <population>Zero participants analyzed. Data was not collected for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LY 2127399 Q2W</title>
            <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
          </group>
          <group group_id="O2">
            <title>LY2127399 Q4W</title>
            <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Anti-double-stranded Deoxyribonucleic Acid Level</title>
          <population>Zero participants analyzed. Data was not collected for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All randomized participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>LY 2127399 Q2W Treatment</title>
          <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
        </group>
        <group group_id="E2">
          <title>LY2127399 Q4W Treatment</title>
          <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
LY2127399: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Placebo: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.</description>
        </group>
        <group group_id="E3">
          <title>LY 2127399 Q2W Follow Up</title>
          <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks. Follow up.</description>
        </group>
        <group group_id="E4">
          <title>LY2127399 Q4W Follow Up</title>
          <description>If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks. Follow up.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="578"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="810"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Haemolytic uraemic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Bundle branch block bilateral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Myocardial fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Tricuspid valve disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Adrenocortical insufficiency acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Mineralocorticoid deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="937"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Implant site erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pelvic mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Nodular regenerative hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blastocystis infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="877"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pyonephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="937"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="578"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="810"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Vulval cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="877"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Bronchial injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Procedural intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Respiratory fume inhalation disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QRS complex shortened</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cholesterosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Ketosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="937"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="578"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>SLE arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="937"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Benign vaginal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="877"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Brenner tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="877"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="760"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="877"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="877"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Carotid artery dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>IIIrd nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Neuropsychiatric lupus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>VIth nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="877"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="877"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blighted ovum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="760"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="877"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="760"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Generalised anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Lupus nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="810"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="877"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="760"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="877"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="877"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="527"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pleural fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Upper airway obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Mucocutaneous ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Precancerous skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Poor venous access</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="464" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="232" subjects_at_risk="578"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="810"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="937"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="937"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="70" subjects_affected="59" subjects_at_risk="937"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="937"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="36" subjects_affected="34" subjects_at_risk="937"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="937"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="937"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="937"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="74" subjects_affected="57" subjects_at_risk="937"/>
                <counts group_id="E2" events="32" subjects_affected="26" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="937"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="83" subjects_affected="63" subjects_at_risk="937"/>
                <counts group_id="E2" events="46" subjects_affected="40" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="33" subjects_affected="27" subjects_at_risk="937"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="64" subjects_affected="56" subjects_at_risk="937"/>
                <counts group_id="E2" events="28" subjects_affected="17" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="142" subjects_affected="104" subjects_at_risk="937"/>
                <counts group_id="E2" events="68" subjects_affected="51" subjects_at_risk="578"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="810"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="158" subjects_affected="106" subjects_at_risk="937"/>
                <counts group_id="E2" events="78" subjects_affected="52" subjects_at_risk="578"/>
                <counts group_id="E3" events="21" subjects_affected="20" subjects_at_risk="810"/>
                <counts group_id="E4" events="18" subjects_affected="16" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="937"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="39" subjects_affected="36" subjects_at_risk="937"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="937"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="937"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="67" subjects_affected="53" subjects_at_risk="937"/>
                <counts group_id="E2" events="34" subjects_affected="28" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="937"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="937"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="937"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="937"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="937"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="578"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="810"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated early due to lack of efficacy in parent studies.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

